138 results about "Blood concentration" patented technology

The invention discloses a method for detecting the concentration of cyclosporine in blood through fluorescence and electrochemical double signals, and belongs to the technical field of biochemical analysis and medical detection. Aiming at the technical problems of insufficient sensitivity and high false positive rate of traditional single-signal detection of blood concentration of cyclosporine, the method comprises the following steps: activating carboxyl microspheres by a coupling agent, fixing double-stranded DNA (deoxyribonucleic acid) formed by a cyclosporine aptamer and an initiator chain, inducing the initiator to release by using a cyclosporine sample, realizing strand displacement through an A2-PEI composite system, and detecting the blood concentration of cyclosporine by using an A < 2 >-PEI composite system. DNA modified cadmium telluride quantum dots are respectively adopted to detect fluorescence signals, eATRP electrochemical signal amplification is carried out to detect electrochemical signals, concentration values obtained by the two signals are verified, and an average value is taken as a result. The method can accurately capture low-concentration cyclosporine signals in blood, eliminates interference of a single method, is mainly used for accurately monitoring the blood concentration of cyclosporine, and provides a reliable detection means for medication safety and curative effect control of cyclosporine in clinical scenes such as organ transplantation.

The invention discloses a construction method of a rivaroxaban population pharmacokinetic model and application of the rivaroxaban population pharmacokinetic model in an individualized medication prediction model, and relates to the field of biological information. According to the invention, a high performance liquid chromatography-tandem mass spectrometry method is adopted to determine the blood concentration of a rivaroxaban taking person, and a DNA sequencing method is adopted to determine the gene polymorphism of related metabolic enzymes CYP3A4 and CYP3A5 and transporters ABCB1 and ABCG2 of the rivaroxaban taking person; collecting data to establish a rivaroxaban group pharmacokinetic model, performing internal verification, and evaluating the stability and prediction performance of the model; in the final PPK model, the influence of the creatinine clearance rate, the ABCB1rs1045642 and the health condition on the clearance rate is the greatest; the experimental verification result shows that the model has good predictability and is accurate and reliable; the method can be applied to an individualized medication prediction model.

To provide an estimation method of a recirculation rate enabling estimation of a recirculation rate without being limited by a preparation location of a blood marker or an arrangement location of detection means of the blood marker.SOLUTION: An estimation method of a recirculation rate includes the steps of: acquiring data representing an amount of change in blood concentration after recirculation when a blood marker is added to blood to be extracorporeally circulated, data representing a relation between an amount of change in blood concentration after recirculation and blood concentration, and data representing a relation between the amount of change in blood concentration after recirculation and a blood flow rate; creating a model by multivariate analysis or machine learning to obtain a regression equation or a conversion model, with the amount of change in blood concentration after recirculation, blood concentration and a blood flow rate used as an explanatory variables and the recirculation rate as an objective variable; acquiring data representing the amount of change in blood concentration, blood concentration and a blood flow rate of blood flowing through an arterial line or a venous line; and inputting treatment data to the regression equation or the conversion model to estimate the recirculation rate.SELECTED DRAWING: Figure 3A

To provide a method and device for predicting plasma concentration transition in combination of multiple drugs, by easily determining Ki, fm in vivo, and making them into a database, since, there has been dynamic prediction using a physiologic medicine speed theory (PBPK) model, as a prediction method of a drug interaction for medical products, however, prediction using an inhibition constant (Ki) of in vitro data and a contribution ratio (fm) of a metabolic enzyme, do not always match increase of clinical AUC.SOLUTION: There is provided a method for determining a parameter of a compartment model from a pharmacokinetic parameter of an interacted drug and interaction drug, then converting the compartment parameter into a PBPK model parameter, then determining by simulation using the PBPK model, a Ki value and fm being AUC increase ratios observed clinically. The acquired parameter is made into a database, and simulation of blood concentration transition of the interacted drug and interaction drug is performed.SELECTED DRAWING: Figure 1

The invention relates to pamoate drug sustained release microspheres and a preparation method thereof. According to the sustained-release microsphere preparation for injection prepared by the preparation method disclosed by the invention, the particle size distribution of the microspheres is relatively narrow, and the release time of active pharmaceutical ingredients can last for about three months to four months. Besides, the microsphere preparation prepared by the invention can maintain stable blood concentration in an animal body, has no large fluctuation of the blood concentration within 3-4 months, and better avoids the occurrence of toxic and side effects.

The invention relates to the technical field of medical instruments, and discloses a dynamic blood glucose monitoring system after kidney transplantation based on artificial intelligence, the system comprises a data acquisition and transmission module, an AI decision support module, a risk early warning and report generation module, a feedback and optimization module and a system integration module; an AI drug disturbance analysis module is arranged, when postoperation blood glucose is monitored in real time, an immunosuppressor-blood glucose dynamic response model is established, the causal relationship between the blood concentration of a specific drug and glucose metabolism is analyzed, and a drug correlation event label is labeled in real time; by means of the method, whether blood glucose fluctuation is triggered by immunosuppressor metabolism abnormality or not can be accurately recognized, it is avoided that drug-induced hyperglycemia is misjudged as an dietary event, the accuracy of treatment intervention decision making is guaranteed, and the rejection risk is reduced.

The invention provides a method for detecting the blood concentration of elacycline in serum. The method comprises the following steps: pretreating a human serum sample; then detecting by adopting liquid chromatography-mass spectrometry, wherein a liquid chromatography condition mobile phase comprises ultrapure water (a mobile phase A) containing 0.1% of formic acid and acetonitrile (a mobile phase B); the temperature of the chromatographic column is kept at 45 DEG C, and the sample size is 2L; the flow velocity of the mobile phase is set to be 0.3 mL / min, and the total operation time is 4.5 minutes; in mass spectrum conditions, a positive electrospray ionization mode is adopted, multiple reaction monitoring (MRM) is adopted, and multi-reaction monitoring is adopted as a scanning mode. The method is high in sensitivity, the lowest quantitative concentration can reach 50 ng / mL, and accurate, rapid and sensitive determination of the elacycline in the human serum can be realized.

The invention provides a loxoprofen sodium double-release capsule micro-tablet and a preparation method of the loxoprofen sodium double-release capsule micro-tablet. Through the synergistic effect of the quick-release micro-tablet and the sustained-release micro-tablet, the quick-release micro-tablet can realize quick release and absorption, and the sustained-release micro-tablet can maintain relatively stable blood concentration for a long time. The administration frequency is reduced, the coordination of the postprandial administration requirement and the dietary habit is ensured, and the occurrence of gastrointestinal tract adverse reactions is reduced. The preparation provided by the invention conforms to the dosage form design of the hour pharmacology, can quickly take effect through administration twice every day, can maintain the blood concentration in the high-incidence time period of night diseases, avoids the disadvantage of taking medicine after meal when the night diseases attack, guarantees the sleep quality, and improves the overall treatment effect. The micro tablet is small in size and easy to swallow, and the medication compliance of patients with dysphagia is obviously improved. Through dosage form design and improvement, unmet clinical requirements are expected to be met by virtue of obvious advantages of the traditional Chinese medicine composition.

The present application relates to the technical field of federated learning, and particularly to a blood drug concentration anomaly analysis method based on federated learning, comprising the following steps: a center server generates and issues a proxy data set without privacy risk to a plurality of medical institution clients; and receiving local prediction logits generated and uploaded by the plurality of medical institution clients after predicting the proxy data set by using local heterogeneous models. In the present application, a dynamically evolving global prototype memory bank is combined for anomaly judgment, a normal prototype benchmark reflecting the latest global state is constructed by periodically fusing feature distributions extracted by each node at different time stages, so that anomaly detection no longer depends on static or isolated rules, but is based on a dynamically updated and collectively agreed dynamic standard, thereby improving the robustness and accuracy of anomaly judgment.

The invention discloses traditional Chinese medicine granules with an auxiliary blood pressure lowering effect and a preparation method thereof. The traditional Chinese medicine granules are prepared by mixing uncaria, scutellaria baicalensis, semen cassiae, the root of kudzu vine, selfheal, leonurus, gastrodia elata, microcrystalline cellulose and a ginseng essential oil slow-release agent and then carrying out granulation and freeze-drying processes. Wherein the ginseng essential oil sustained-release agent is prepared by adopting ginseng essential oil and Tween 80 to form a nano microemulsion, then wrapping the nano microemulsion in a chitosan and sodium linoleate compound coating solution and performing freeze drying, and the ginseng essential oil sustained-release agent prepared in the mode can effectively prevent the ginseng essential oil from being in contact with oxygen to cause an oxidation phenomenon; the core functions of the ginseng essential oil sustained-release preparation are to control the release rate of active ingredients, reduce the administration frequency, maintain more stable blood concentration or active ingredient level, prolong the retention time of the medicine in gastrointestinal tracts, further promote absorption and improve the bioavailability.

The present application relates to an extracorporeal blood treatment system (50) for treating a subject, the system comprising: an extracorporeal blood circuit (52); a dialysate fluid circuit (54); the extracorporeal blood circuit and the dialysate fluid circuit being separated by a membrane (56) of a filtration unit (58); at least one blood pump (60) for controlling the flow of blood through the blood circuit; at least one dialysate fluid pump (62) for controlling the flow of dialysate fluid through the dialysate fluid circuit (54); a system computing unit (64) operatively connected to the blood pump and to the dialysate fluid pump, the system computing unit having at least one input; wherein the system computing unit is adapted to receive a desired blood concentration of glutamine GLN b , to receive a desired blood concentration of glucose GLUCOSE b , and to receive a desired blood concentration of ketone bodies KETONE b ; the system computing unit being adapted to control the blood pump and the dialysate fluid pump such that an actual concentration value of glutamine GLN a is driven to approach GLN b , and an actual concentration value of glucose GLUCOSE a is driven to approach D b , and an actual concentration value of ketone bodies is driven to approach KETONE a . The present application relates to a treatment device for use in an extracorporeal blood treatment system, a method for treating cancer using the system, a controller for controlling the method and a dialysis liquid suitable for use in the method.

The invention relates to the technical field of medical examination, and discloses a method for rapidly measuring the blood concentration of posaconazole and application of the method. According to the method for rapidly determining the blood concentration of posaconazole and the application of the method, compared with chromatography in the prior art, the adopted mobile phase is relatively single, the configuration time of the mobile phase is saved, and meanwhile, the fluctuation of a detection result caused by the configuration of the mobile phase is reduced to the greatest extent; the stability of the method is further enhanced; meanwhile, compared with other liquid chromatography methods, the detection method has the advantages that the single-needle sample injection time is short, the reagent preparation is simple, no endogenous and common exogenous substance interference exists around the target peak of posaconazole, and the like, and the detection efficiency and the accuracy of the detection result are improved.

The invention relates to a riociguat prodrug as shown in a formula X or pharmaceutically acceptable salt thereof, a preparation method, an intermediate and a pharmaceutical composition thereof. The prodrug takes amino of riociguat as a modification site and is connected through an ester carrier, drug release is triggered by utilizing lung amidase, and lung targeted delivery is realized by adjusting a lipid-water partition coefficient. Pharmacokinetic studies show that the prodrug can significantly improve the drug concentration and total exposure of the lung, reduce the blood concentration of the whole body, and show excellent lung targeting characteristics. The invention also provides a pharmaceutical composition (preferably an inhalation preparation) containing the prodrug, and an application of the prodrug in preparation of drugs for preventing, treating, treating or relieving pulmonary arterial hypertension of patients. .

The invention belongs to the technical field of biological medicine, and particularly relates to a ganoderma lucidum polysaccharide sustained-release liver protection preparation and a preparation method thereof.The preparation comprises a pellet, the pellet comprises a pellet core, a medicine layer, an inner sustained-release layer and an outer mucous membrane attachment enteric-coated composite layer, and the pellet core is coated with the medicine layer, the inner sustained-release layer and the outer mucous membrane attachment enteric-coated composite layer in sequence; the medicine layer contains high-purity ganoderma lucidum polysaccharide; the inner slow-release layer is composed of ethyl cellulose, triethyl citrate and polyethylene glycol 4000; the outer mucous membrane attachment enteric composite layer is formed by compounding chitosan and a pH sensitive polymer, preferably, an in-situ network structure is formed through calcium ion crosslinking, and the outer mucous membrane attachment enteric composite layer has the enteric function and the mucous membrane attachment function. The invention aims to solve the problems that the existing ganoderan preparation is too fast in release, large in blood concentration fluctuation and short in action time. Through the synergistic effect of the structures, the ganoderma lucidum polysaccharide sustained-release liver protection preparation is stable in stomach, targeted in intestinal tract release and retained in mucous membranes, the sustained-release effect of 12 h or above is achieved, and the bioavailability and the liver protection curative effect are remarkably improved.

The present invention relates to a multiple controlled-release tablet composition of ruxolitinib or a pharmaceutically acceptable salt thereof, which is useful for treating Janus kinase-associated diseases such as myeloproliferative disorders, and a method for producing the same. More specifically, the present invention relates to a multiple controlled-release tablet composition and a method for producing the same, which exhibits a maximum drug blood concentration similar to that of commercially available immediate-release formulations, while controlling the drug release rate so as to efficiently maintain the drug at or above the effective blood concentration in the body, thereby enabling once-daily administration, unlike commercially available formulations that are administered twice daily.

To provide a novel material or composition that is effective in preventing or alleviating dyslipidemia. [Solution] A material or composition containing live or dead yeast cells or yeast hydrolysates for preventing or alleviating dyslipidemia. Dyslipidemia here refers to one or more abnormalities in blood concentrations of LDL cholesterol (bad cholesterol), HDL cholesterol (good cholesterol), and triglycerides (neutral fats). Zygosaccharomyces rouxii or Pichia are preferred as the yeast. The yeast is preferably of food origin and preferably intended for human consumption.

The embodiment of the present application provides a medical detection device, comprising: a shell; a pressure measuring component, which is installed on the outer wall of the shell and is used for measuring the pressure of the environment outside the shell; and a concentration measuring component, which is installed on the outer wall of the shell and is used for measuring the concentration of a parameter to be measured in the environment outside the shell. The medical detection device in the embodiment of the present application can realize the detection of various parameters (including pH value, occult blood concentration, pepsin concentration and trypsin concentration) in the digestive tract, thereby improving the accuracy of the detection result of the medical detection device on the digestive tract. Meanwhile, the medical detection device can realize the measurement of the pressure in the digestive tract, thereby further improving the accuracy of the detection result. Moreover, the medical detection device can reduce the medical detection procedure and the number of devices required in the detection process, thereby saving the cost.

The invention relates to a preparation method and application of a suvortinib standard substance in human serum, and belongs to the field of medical examination. The standard substance is characterized by comprising the following three levels of suvaltinib solutions: a level 1: 10.00-50.00 [mu] g / L, a level 2: 10.00-50.00 [mu] g / L, and a level 3: 10.00-50.00 [mu] g / L; the level 2 is 450.00 to 750.00 [mu] g / L; the level is 3: 1200.00 to 2000.00 [mu] g / L; wherein the level 1 corresponds to the concentration range of the blood concentration trough of the suvortinib in the serum of a patient taking the medicine; the level 2 is an effective treatment blood concentration range; and the level 3 is the peak concentration range of the blood concentration. The standard substance can be used as a conventional detection limit and a reportable range of suvortinib in human serum. The standard substance has good uniformity, stability and interoperability, and can be applied to the fields of accuracy evaluation of blood concentration detection, detection result value traceability, performance evaluation of medical equipment, instrument calibration, research and development of medical equipment and the like.

The invention relates to the technical field of drug release adjustment, and particularly discloses a drug release adjustment method and system based on sweat pH value and temperature, and the method comprises the steps: S1, obtaining sweat pH value and skin surface temperature information of a region, and obtaining a signal A and a signal B respectively; s2, preprocessing to obtain a stabilized signal; s3, calculating an instantaneous drug release rate, and quantifying to obtain a current nano preparation release efficiency coefficient; S4, driving a microneedle channel to open and control to obtain a blood concentration; s5, sampling and detecting the released blood concentration to obtain a feedback concentration signal; s6, updating the release efficiency coefficient to obtain a nano preparation release efficiency coefficient of a new period; dual signals of sweat pH and skin surface temperature are synchronously collected, stable input is generated after pretreatment, subtle changes of body surface and in-vivo physiological states can be reflected in real time, and therefore richer and more reliable basis is provided for drug release decision, and drug delivery precision is effectively improved.

The invention provides a construction method of an organ transplantation perioperative period precise drug delivery model, a precise drug delivery prediction device and electronic equipment, and belongs to the technical field of crossing of precise medicine and pharmacology. A primary absorption and elimination two-atrioventricular model with lagging time is adopted as a basic model, covariables are introduced, model fitting is carried out, and an organ transplantation perioperative period precise drug delivery model is constructed. According to the method, internal verification and external verification are carried out on the basis of a goodness-of-fit diagnostic diagram, a prediction correction visual prediction test, a bootstrap method and a normalized prediction distribution error, finally Monte Carlo simulation is carried out to design an administration scheme, an individualized administration scheme is recommended for a patient in the perioperative period, and the model obtained through the construction method provided by the invention has the advantages of high accuracy and high reliability. The adverse reaction occurrence rate of the mycophenolate mofetil capsule can be greatly reduced, the MPA exposure compliance rate is improved, and the occurrence rate of adverse events after organ transplantation is reduced.

The invention relates to the technical field of pharmaceutical preparations, and particularly discloses an arginine ibuprofen biphasic sustained release preparation and a preparation method thereof. Through a two-phase system of quick-release particles and slow-release particles, the problems that a traditional preparation takes effect slowly, is short in medicine effect and poor in taste are solved. Wherein the quick-release granules are prepared by mixing and granulating ibuprofen arginine, a filling agent, an adhesive and a natural flavoring agent, so that the effective blood concentration can be ensured to be reached within 15 minutes after the medicine is orally taken so as to quickly relieve pain, and the bad flavor of the medicine can be synchronously covered; the sustained-release granules are based on an ibuprofen arginine drug-loading core, the outer layer of the sustained-release granules is coated with a sustained-release film formed by a sustained-release agent and a plasticizer, and the effective blood concentration can be stably maintained for 6-8 hours, so that the medicine taking frequency is reduced, the sustained-release granules only need to be taken for 1-2 times every day, the medication compliance of a patient is greatly improved, and the sustained-release granules are suitable for clinical application. The traditional Chinese medicine composition is especially suitable for clinical scenes needing long-term or repeated analgesia such as chronic arthritis and postoperative pain, has excellent safety and practicability, and has a wide market application prospect.

According to the technical scheme, the constant volume device is characterized by comprising a base, two supporting plates are fixedly mounted on the top face of the base, a mounting plate is fixedly mounted between the supporting plates, and a constant volume bin is fixedly mounted in the mounting plate; the constant volume assembly is arranged above the base and used for carrying out constant volume on the blood medicine content in the constant volume bins, by arranging the constant volume assembly, the blood medicine content stored in the two constant volume bins can be limited, the blood medicine content stored in the two constant volume bins can be consistent, and during detection, the blood medicine content in the two constant volume bins can be accurately detected. The content of collected blood medicine added in blood medicine detection can be accurately controlled, the situation that residual air exists in the constant volume bin and influences the collection amount during blood medicine concentration detection is avoided, the phenomenon that detection results have errors due to the fact that the addition content of the detected blood medicine is different is effectively prevented, and the accuracy of the detection results is effectively improved.

The invention belongs to the technical field of biological detection and pharmaceutical analysis, and particularly relates to a method for determining dulcitine in blood plasma. The concentration of the dulcitine in the blood plasma is detected by adopting an ultra-high performance liquid chromatography-mass spectrometry method, a new guarantee means is provided for the medication safety of the tripterygium glycosides tablets, and meanwhile, a new method is provided for measuring the blood concentration of the dulcitine.

The invention provides a method for detecting the blood concentration of Shenfukang capsules. The method comprises the following steps: respectively preparing a first detection specimen containing a serum sample and a second detection specimen containing a urine sample; the method comprises the following steps: taking a first sample to be detected and a second sample to be detected, injecting a Supersil ODS 2 chromatographic column, taking 0.1% phosphoric acid aqueous solution-methanol as a mobile phase, respectively detecting the chromatographic peak of calycosin in the first sample to be detected and the chromatographic peak of rhein in the second sample to be detected, and calculating the concentration of calycosin and the concentration of rhein in the samples according to the chromatographic peaks; the chromatographic conditions of the first detection sample are that the detection wavelength is 260 nm, and gradient elution is carried out; the chromatographic conditions of the second detection sample are as follows: the detection wavelength is 254 nm, and isocratic elution is performed. The method has excellent repeatability and high sensitivity, the operation process is simple and easy to implement, the administration scheme can be accurately adjusted and an individualized administration strategy can be implemented in close combination with clinical manifestation and various inspection results of a patient, so that the safety and effectiveness of the medication process are ensured, and the method is suitable for clinical popularization and application. And a reliable medication guarantee is provided for the treatment of patients with chronic kidney diseases.

A brivaracetam pharmaceutical composition contains an active pharmaceutical ingredient, a matrix forming agent, and a swelling agent. It has a sustained release effect and has a more flat release curve compared with a common gel skeleton sustained-release preparation, and thus achieves the purposes of reducing the release rate of the medicament, controlling the in vivo effective dosage of the medicament, stabilizing the blood concentration, reducing toxic and side effects and reducing the times of daily administration.

The invention provides a preparation form and a preparation method of metformin. The preparation is composed of a tablet core and a controlled release film wrapping the tablet core, and the controlled release film is provided with at least one channel which allows the metformin or the pharmaceutically acceptable salt of the metformin to be released from the tablet core in a water phase environment. The design of the dosage form can control the release of the metformin or the pharmaceutically acceptable salt of the metformin to be less than 30% in 4 hours and less than 92% in 24 hours in a medium with the temperature of 37 DEG C and the pH value of 6.8. The design of the dosage form can control the plasma concentration of the metformin to reach the peak value at about 8-24 after the metformin or the pharmaceutically acceptable salt of the metformin is taken for a single time.

The invention provides an SERS (Surface Enhanced Raman Scattering) substrate and a detection method for the blood concentration of epirubicin, and belongs to the technical field of detection.The SERS substrate is prepared by the following steps: firstly, respectively preparing 40nm and 20nm gold nanoparticles through a sodium citrate reduction method, and constructing the SERS substrate on a silicon dioxide sheet through ABA sandwich dispensing; an epirubicin blood sample is pretreated through an acetonitrile precipitation method and then dropwise added to the substrate to be dried away from light, and the 1236 cm <-1 > characteristic peak intensity is detected through a 785 nm Raman spectrum. By establishing a quantitative curve of epirubicin concentration and peak intensity in serum, rapid quantitative detection of clinical samples is realized. The method is simple in sample treatment, high in detection sensitivity, good in repeatability, consistent with LC-MS / MS results, and suitable for bedside treatment drug monitoring.

The invention provides a gel emplastrum for treating oxaliplatin peripheral neurotoxicity and a preparation method, and relates to the field of traditional Chinese medicine, the gel emplastrum comprises a backing layer, an emplastrum layer and an anti-sticking layer; the paste layer is a gel layer formed by traditional Chinese medicine extract and a matrix for loading the traditional Chinese medicine extract; the traditional Chinese medicine extract is prepared from a traditional Chinese medicine composition; the traditional Chinese medicine composition comprises astragalus membranaceus, angelica sinensis, vinegar rhizoma sparganii, vinegar curcuma zedoary, cassia twig, achyranthes bidentata and pheretima in a mass ratio of 6: 3: 2: 2: 2: 4: 2. The matrix comprises a framework material, a cross-linking agent, a cross-linking regulator, a thickening agent, a humectant, a complexing agent, pure water, a preservative, a penetration enhancer, a thermal inductance regulator and a high-performance emulsifying thickening agent. The problems that in the prior art, a formula for promoting blood circulation to remove blood stasis is inconvenient to use in a soaking and washing main use mode, the patient compliance is poor, the speed of medicine entering the body of a patient is not easy to control, the blood concentration in the body of the patient is difficult to maintain stably, and the peripheral neurotoxicity treatment progress is difficult to control can be solved.

The invention relates to a crystal form of a bipyrimidine compound as well as a preparation method and application thereof. In particular, the present invention relates to a crystalline form I of 4 '-cyclopropyl-5, 6'-dimethoxy-N-((4-(1-methyl-4-(trifluoromethyl)-1H-imidazol-2-yl) bicyclo [2.2. 2] oct-1-yl) methyl)-[2, 5 '-bipyrimidinyl]-4-amine, a crystalline form II of 4'-cyclopropyl-5, 6 '-dimethoxy-N-((4-(1-methyl-4-(trifluoromethyl)-1H-imidazol-2-yl) bicyclo [2.2. 2] oct-1-yl) methyl)-[2 An X-ray powder diffraction pattern of the compound comprises characteristic peaks at diffraction angles (2 theta) of 6.378 + / -0.2 degrees, 9.521 + / -0.2 degrees, 15.721 + / -0.2 degrees, 16.379 + / -0.2 degrees, 16.981 + / -0.2 degrees, 17.560 + / -0.2 degrees, 19.080 + / -0.2 degrees and 22.200 + / -0.2 degrees. The crystal form I is high in stability, high in solubility, high in blood concentration, high in bioavailability and excellent in pharmacological action, so that the crystal form I is suitable for pharmaceutical preparations.

The invention provides a construction method of a precise medication model for mycophenolic acid drugs, a prediction device and electronic equipment. Belongs to the cross technical field of precision medicine and pharmacology. The construction method of the precise medication model for the mycophenolic acid drugs comprises the following steps: S1, acquiring clinical data of a patient; s2, collecting blood samples at different time points after the patient takes the medicine, and detecting the blood concentration of the mycophenolic acid medicine; s3, the non-atrioventricular model is used as a basic model, multiple linear regression analysis is carried out, a precise medication model for the mycophenolic acid drugs is established, and a mathematical model of the precise medication model for the mycophenolic acid drugs is shown as a formula (1). By the adoption of the accurate medication model for the mycophenolic acid drugs, the blood sampling frequency for monitoring the blood concentration of the mycophenolic acid drugs can be reduced, the workload of medical workers is reduced, the pain of patients is relieved, and the compliance of the patients is improved.